Sonova outlines hearing-care strategy, shares in focus on the SIX Swiss Exchange

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:28.

Sonova Holding AG (CH0012549785) remains one of the larger healthcare equipment names on the SIX Swiss Exchange, with the stock included in the Swiss Market Index alongside peers such as Roche and Novartis. The Swiss hearing-care specialist has used recent investor events to refine its growth strategy and capital allocation priorities, which continue to draw analyst attention.

What recent communications show

According to a recent overview of analyst views, Sonova has reiterated its focus on premium hearing instruments, cochlear implants and audiological services, underpinned by investments in innovation and distribution. The company highlighted medium-term ambitions for profitable growth supported by its global retail network and recurring service revenues, which position it in the broader European medtech peer group that includes firms such as Demant and GN Store Nord.

Sonova also emphasized disciplined capital allocation, balancing research and development spending, bolt-on acquisitions and shareholder returns through dividends and buybacks, in line with typical SMI blue-chip practice. This strategic mix is designed to support earnings resilience across economic cycles, a point that features prominently in several recent analyst presentations and consensus summaries.

How analysts value the stock

UBS has recently reiterated a Buy rating on Sonova, with a price target in the low-300 Swiss franc range, according to consensus aggregators that compile major investment bank views. Other banks such as Vontobel and ZKB also maintain broadly constructive stances, reflecting confidence in Sonova’s ability to defend margins in the competitive global hearing-care market. An overview of analyst opinions cited by ad-hoc-news shows that the stock is generally rated positively within the SMI healthcare segment.

Several research houses point to Sonova’s diversified exposure across hearing aids, implants and services as a key factor in their models, noting that the company benefits from structural drivers such as aging populations and higher screening rates. In this context, Sonova is often mentioned alongside medtech peers when investors compare valuation multiples and long-term earnings growth assumptions.

The products behind the ticker

Sonova generates most of its revenue from hearing instruments under brands such as Phonak, including rechargeable behind-the-ear devices and custom in-ear systems. The group also offers cochlear implant solutions and runs audiological care networks, which together create recurring revenue streams from fittings, upgrades and ongoing patient services.

Where the shares trade today

Sonova shares (CH0012549785) trade on the SIX Swiss Exchange in Zurich at 250 CHF as of 2026-06-22, 17:30, giving the company a market capitalization of around 15 billion CHF.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.